Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus
NCT00138281Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in influenza comparing FluMist with Fluzone (2 arms). Primary endpoint: CD4 and CD8 T-cell, B-cell, NK-cell and homing receptor responses at Day 28. Status: completed.
02
Drugs
live attenuated influenza vaccineFluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00138281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138281.